Fig. 1 · Structure

Documents & Downloads

PNU-120596

Cat. No. A11203 CAS 501925-31-1

Nicotinic (α7) Receptor Modulator

PNU-120596 is a positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptors.

In Stock

Publications for PNU-120596

1 publication citing this product

  1. Hugo R Arias, .et al. , Br J Pharmacol, 2022, Sep 9 PMID: 36082615

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

PNU-120596 enhances agonist-evoked α7 nicotinic acetylcholine receptor currents and prolongs the response. In wild-type human α7 receptors expressed in oocytes, 1 μM PNU-120596 potentiated ACh- and choline-evoked currents; no detectable potentiation occurred at α4β2, α3β4 or α9α10 under the tested conditions. [1]

Transmembrane residues contribute to PNU-120596 modulation: rat α7 A225D and M253L mutations markedly reduced potentiation of submaximal ACh responses. This identifies functional determinants without establishing a physical binding pocket. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
α7 nAChR EC50 216 nM

PNU-120596 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of PNU-120596 from 3 published references. In vitro models include Xenopus oocytes expressing rat wild-type or point-mutated α7 nAChRs; Xenopus laevis oocytes expressing rat α1β2γ2L GABAA receptors.

PNU-120596 In Vitro Studies

PNU-120596 also weakly modulates recombinant rat α1β2γ2L GABAA receptors. At 50 μM, it increased low-GABA responses to 133 ± 11% of control (mean ± SEM; n = 5). Its potentiation concentration-response fits did not converge, and it reduced steady-state responses to saturating GABA. These findings limit broad claims of target exclusivity. [3]

Agonist-dependent potentiation and nAChR subtype comparison

Cell-based study · Xenopus oocytes expressing wild-type human α7, α4β2, α3β4 or α9α10 nAChRs [1]

PNU-120596 increased α7 agonist-evoked peak currents and prolonged responses. At the tested concentration, no detectable potentiation was found for the other three nAChR subtypes.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Peak-current potentiation and response durationQualitative current response Increased α7 responses; no detectable potentiation at α4β2, α3β4 or α9α10; n = 4 per subtype in Figure 2D[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM PNU-120596
Exposure duration
20 s pretreatment; 3 s agonist test pulses
Method
Two-electrode voltage clamp; agonist responses before and after PNU-120596
Vehicle
Compounds diluted in OR2 recording medium; no stock-solvent fraction specified for this selected assay
Co-treatment
ACh 100 μM or choline 1 mM for α7; subtype comparison used ACh 100 μM (α7), 50 μM (α4β2 and α3β4), or 10 μM (α9α10)
Reported limits
No numerical α7 fold increase estimated from bars. Figure 2C has inconsistent replicate descriptions, so its fitted ACh potency values are not adopted.
Methods and source locations

Compound reported in the paper: PNU-120596; Compound label in the paper: PNU-120596

Evidence concerns the named research compound in the reported model; it does not validate an Adooq batch or establish human efficacy.

Figure 2A–B,D; associated Results; Materials and Methods: Oocyte preparation and recording

Peak-current potentiation and response duration: Within-oocyte agonist controls followed by PNU-120596 exposure; subtype comparison in a separate oocyte batch — Figure 2A–B,D and associated Results; Materials and Methods: Oocyte preparation and recording

Transmembrane mutations reduce α7 potentiation

Cell-based study · Xenopus oocytes expressing rat wild-type or point-mutated α7 nAChRs [2]

Compared with wild-type α7, A225D and M253L markedly reduced maximal potentiation by PNU-120596. These functional determinants do not alone prove the physical location of a ligand-binding pocket.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Maximal fold potentiation of EC20 ACh responsesFold potentiation Wild type: 36.7 ± 4.1; A225D: 3.2 ± 0.3; M253L: 4.1 ± 0.8 (fold effects)[2]

Literature-Reported Treatment Conditions

Treatment concentration
PNU-120596 0.1–30 μM
Exposure duration
Not specified in the selected main-text mutagenesis protocol
Method
Two-electrode voltage clamp
Vehicle
Recording solvent fraction not specified in the selected main text
Co-treatment
Submaximal (EC20) ACh, defined separately for receptor constructs
Reported limits
SI Fig. S2 was not retrieved; exact construct-specific EC20 concentrations and any additional SI protocol details are unavailable here.
Methods and source locations

Compound reported in the paper: PNU-120596; Compound label in the paper: PNU-120596

Evidence concerns the named research compound in the reported model; it does not validate an Adooq batch or establish human efficacy.

Figure 2; Table 1; associated Results; Methods Materials and Xenopus Oocyte Electrophysiology

Maximal fold potentiation of EC20 ACh responses: Concentration-response electrophysiology; Table 1 values are mean ± SEM from three to seven independent experiments; Figure 2 describes five to seven different oocytes per curve — Results: Identification of Amino Acids Required for Allosteric Modulation; Table 1; Figure 2

Weak GABAA modulation with concentration-response limits

Cell-based study · Xenopus laevis oocytes expressing rat α1β2γ2L GABAA receptors [3]

PNU-120596 weakly potentiated submaximal GABA responses and very weakly directly activated the receptor. Potentiation fits failed to converge. With saturating GABA, the steady-state current decreased instead of increasing.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Potentiation of low-GABA steady-state responsePercent of control 133 ± 11% of control; n = 5 oocytes at 50 μM PNU-120596 (mean ± SEM)[3]
Direct activation relative to reference responsePercent of reference 0.38 ± 0.09%; n = 5 oocytes (mean ± SEM), 50 μM PNU-120596[3]
PNU-120596 potentiation concentration-response fitFit limitation Fits did not converge; no potentiating EC50 assigned[3]
Steady-state response with saturating GABAPercent of control 90 ± 2% of control (mean ± SEM) with 50 μM PNU-120596[3]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM for direct activation and low-/saturating-GABA comparisons; 1–50 μM in potentiation concentration-response measurements
Exposure duration
30–60 s direct activation; 20–40 s concentration-response applications, separated by 1–3 min washouts
Method
Two-electrode voltage clamp at −60 mV
Vehicle
Electrophysiology stock solvent/final vehicle fraction not specified in the read Methods; the 0.1% DMSO/HBS formulation belongs to the separate fluorescence assay
Co-treatment
Low GABA (2–5 μM for Figure 4; 2–4 μM in Figure 5 caption); saturating GABA 1 mM; reference response 1 mM GABA + 50 μM propofol
Reported limits
No valid PNU-120596 potentiating EC50 obtained; no direct inference of in vivo GABAA contribution.
Methods and source locations

Compound reported in the paper: PNU-120596; Compound label in the paper: PNU-120596

Evidence concerns the named research compound in the reported model; it does not validate an Adooq batch or establish human efficacy.

Figures 3–6 and associated Results; Methods: electrophysiological recordings, data/statistical analysis, Materials

Potentiation of low-GABA steady-state response: Peak GABA + PNU-120596 current divided by preceding GABA steady-state current; 100% means no change — Results α7-PAMs activate and potentiate the α1β2γ2L GABAAR; Figure 4

Direct activation relative to reference response: Normalized to peak response to 1 mM GABA + 50 μM propofol in the same oocytes — Figure 3 and associated Results; electrophysiological Methods

PNU-120596 potentiation concentration-response fit: Coapplication of 1–50 μM PNU-120596 with low GABA — Figure 5 and associated Results

Steady-state response with saturating GABA: Coapplication during steady-state response to 1 mM GABA; individual replicate count not specified in the adjacent sentence — Figure 6 and associated Results

PNU-120596 In Vivo Studies

In anesthetized male Sprague Dawley rats, acute intravenous PNU-120596 reversed part of an amphetamine-induced auditory gating deficit. Reported reversal was 47 ± 3.8% at 0.3 mg/kg and 37 ± 4.2% at 0.1 mg/kg (mean ± SEM; n = 6 per dose). These are acute circuit-level findings in a pharmacological model. [1]

Reversal of amphetamine-induced auditory gating deficits

Animal study · Male Sprague Dawley rats (250–300 g), anesthetized with chloral hydrate; hippocampal CA3 auditory evoked potentials [1]

Intravenous PNU-120596 partially reversed the amphetamine-induced gating deficit relative to vehicle. This circuit-level pharmacology model does not establish treatment of a human psychiatric disorder.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Reversal of amphetamine-induced gating deficitPercent reversal 0.3 mg/kg i.v.: 47 ± 3.8% reversal, n = 6, p < 0.01; 0.1 mg/kg i.v.: 37 ± 4.2% reversal, n = 6, p < 0.05[1]

Conditions shared by the study groups

Route
Intravenous
Frequency
Acute administration
Treatment course
Given after d-amphetamine 1 mg/kg i.v.; recording began 5 min after treatment
Vehicle
5% DMSO and 5% Solutol in PBS (Methods; Figure 8 caption abbreviates as PBS)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Acute intravenous PNU-120596 after amphetamine
PNU-120596 0.1, 0.3 or 1 mg/kg
Vehicle 1 ml/kg i.v., n = 8 in Figure 8C; pretreatment control and post-amphetamine measurements1 mg/kg significantly reversed the deficit (n = 7), whereas vehicle did not improve gating. Text reports 47 ± 3.8% reversal at 0.3 mg/kg and 37 ± 4.2% at 0.1 mg/kg (n = 6 each; SEM).[1]
Acute intravenous PNU-120596 after amphetamine
Model: Anesthetized male Sprague Dawley rats with amphetamine-induced auditory gating impairment
Reported limits: No exact 1 mg/kg percentage reversal extracted from the graph. Caption/Methods formulation difference retained.
Methods and source locations

Compound reported in the paper: PNU-120596; Compound label in the paper: PNU-120596

Evidence concerns the named research compound in the reported model; it does not validate an Adooq batch or establish human efficacy.

Figure 8A–C; associated Results; Materials and Methods: Auditory gating experiments in anesthetized rats

Reversal of amphetamine-induced gating deficit: Gating calculated as (1 − test amplitude/conditioning amplitude) × 100; efficacy expressed as percentage reversal; values reported with SEM — Results: Effects of PNU-120596 on hippocampal auditory gating in anesthetized rats; Figure 8; auditory gating Methods

Acute intravenous PNU-120596 after amphetamine · Figure 8A–C and Results; auditory gating Methods

Specifications

Manufacturer Adooq Bioscience
Actions Modulator
CAS Number 501925-31-1
Applications Nicotinic (α7) Receptor Modulator
Formula C13H14ClN3O4
Molecular Weight 311.72
SMILES
CC1=CC(=NO1)NC(=O)NC2=CC(=C(C=C2OC)OC)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 53 mg/mL (170.02 mM)
Water Insoluble
Ethanol 1 mg/mL (3.2 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

PNU-120596 Research References

  1. [1] Raymond S Hurst, Mihaly Hajós, Mario Raggenbass, et al. A Novel Positive Allosteric Modulator of the α7 Neuronal Nicotinic Acetylcholine Receptor: In Vitro and In Vivo Characterization The Journal of Neuroscience (2005). PMID: 15858066 DOI: 10.1523/JNEUROSCI.5269-04.2005 Source material
  2. [2] Gareth T Young, Ruud Zwart, Alison S Walker, et al. Potentiation of α7 nicotinic acetylcholine receptors via an allosteric transmembrane site Proceedings of the National Academy of Sciences of the United States of America (2008). PMID: 18791069 DOI: 10.1073/pnas.0804372105 Source material
  3. [3] Hugo R Arias, Allison L Germann, Spencer R Pierce, et al. Modulation of the mammalian GABAA receptor by type I and type II positive allosteric modulators of the α7 nicotinic acetylcholine receptor British journal of pharmacology (2022). PMID: 36082615 DOI: 10.1111/bph.15948 Source material

Publications

1 publication citing this product

  1. Hugo R Arias, .et al. , Br J Pharmacol, 2022, Sep 9 PMID: 36082615

Added to your cart

View Cart Checkout
Loading...